Key Details
Price
$3.13Annual ROE
-38.16%Beta
1.72Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial.
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor.
Repare Therapeutics Inc. results from phase 1 MYTHIC study, using lunresertib + camonsertib for the treatment of platinum-resistant ovarian and endometrial cancer with genomic alterations, are expected in Q4 of 2024. Preliminary RECIST response data from 10 patients using the lunresertib + camonsertib combination for ovarian and endometrial cancer patients was 50%. The global ovarian cancer market is expected to reach $11.18 billion by 2029.
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company's camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of the TRESR clinical trial. “Camonsertib has demonstrated a promising signal of prolonged progression free survival in patients with ATM-mutated NSCLC in our ongoing TRESR clinical trial. We are.
Repare (RPTX) rises 14% as the FDA grants Fast Track designation to its investigational lunresertib/camonsertib combo to treat adult ovarian cancer patients in the United States.
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib (RP-6306) in combination with FOLFIRI for the treatment of advanced solid tumors has been selected for a poster presentation at the European Society of Medical Oncology (ESMO) Gastrointestinal (GI) Cancers Congress 2024, being held June 26-29 in Munich,.
Repare Therapeutics Inc. (RPTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repare Therapeutics Inc. (RPTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.
Repare Therapeutics presented preliminary results from the phase 1 MYTHIC study using the lunresertib and camonsertib combination for the treatment of patients with multiple solid tumor types. The biotech plans to complete the phase 1 expansion portion of the phase 1 MYTHIC study and release results in 2024. Plus, potentially initiating late-stage trials in 2024 thereafter. Highly impressive data from the lunresertib and camonsertib combination was observed in patients with gynecological tumors, where the OR was 60%.
FAQ
- What is the primary business of Repare Therapeutics?
- What is the ticker symbol for Repare Therapeutics?
- Does Repare Therapeutics pay dividends?
- What sector is Repare Therapeutics in?
- What industry is Repare Therapeutics in?
- What country is Repare Therapeutics based in?
- When did Repare Therapeutics go public?
- Is Repare Therapeutics in the S&P 500?
- Is Repare Therapeutics in the NASDAQ 100?
- Is Repare Therapeutics in the Dow Jones?
- When was Repare Therapeutics's last earnings report?
- When does Repare Therapeutics report earnings?
- Should I buy Repare Therapeutics stock now?